![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C13H8ClN5O |
Molar mass | 285.69 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
CGS-15943 is adrug which acts as apotent and reasonably selectiveantagonist for theadenosinereceptorsA1 andA2A, having aKi of 3.3nM at A2A and 21nM at A1. It was one of the firstadenosine receptor antagonists discovered that is not axanthine derivative, instead being a triazoloquinazoline.[1][2] Consequently, CGS-15943 has the advantage over most xanthine derivatives that it is not aphosphodiesterase inhibitor, and so has more a specific pharmacological effects profile. It produces similar effects tocaffeine in animal studies, though with higher potency.[3][4][5][6][7]
![]() | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
![]() | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |